论文部分内容阅读
盈利动能大幅下降是华海药业被剔除出166的主要原因。近一周内国信证券将其2011年盈利预测调低至0.41元。公司是全球最大的普利类产品供应商,享有“普利专家”之美誉。沙坦类原料药生产规模、产品质量和品种在国内市场上占有绝对优势,是公司近几年业绩快速增长的主要动力。
The sharp decline in earnings kinetic energy is the main reason that Huahai Pharmaceutical was excluded from the 166. In the recent week, Guosen Securities adjusted its 2011 earnings forecast to 0.41 yuan. The company is the world’s largest provider of Puli products, enjoy “Puli experts ” reputation. The production scale, product quality and varieties of sartan APIs occupy the absolute superiority in the domestic market, which is the main driving force for the rapid growth of the company in recent years.